J. Solsky

Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment

J. Grippo, K. Nieforth, P. Martin, 2013, Antimicrobial Agents and Chemotherapy.

Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir

R. Gieschke, S. Sacks, C. Rayner, 2008, Drug safety.

Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.

E. Snoeck, Navita L. Mallalieu, B. Brennan, 2016, British journal of clinical pharmacology.

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

D. Dieterich, S. Passe, S. Mauss, 2004, AIDS.

Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

C. Bernaards, K. Beavers, E. Lawitz, 2011, Patient preference and adherence.

646 RATE OF INTERSTITIAL PNEUMONITIS AMONG HEPATITIS VIRUS C-INFECTED PATIENTS TREATED WITH PEGYLATED INTERFERON

M. Schaerer, J. Solsky, Michael Peng, 2009 .

Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir

R. Gieschke, S. Sacks, C. Rayner, 2008, Drug safety.